Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
4.26
Dollar change
+0.49
Percentage change
13.03
%
Index- P/E- EPS (ttm)-12.97 Insider Own25.71% Shs Outstand1.17M Perf Week2.93%
Market Cap4.99M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.87M Perf Month34.21%
Income-15.19M PEG- EPS next Q- Inst Own3.22% Short Float2.74% Perf Quarter25.70%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio1.00 Perf Half Y-44.66%
Book/sh1.65 P/B2.58 EPS next Y- ROA-103.68% Short Interest0.02M Perf Year-46.74%
Cash/sh7.81 P/C0.55 EPS next 5Y- ROE-164.09% 52W Range2.40 - 11.77 Perf YTD33.12%
Dividend Est.- P/FCF- EPS past 5Y-20.69% ROI-785.26% 52W High-63.81% Beta1.34
Dividend TTM- Quick Ratio1.25 Sales past 5Y0.00% Gross Margin- 52W Low77.40% ATR (14)0.56
Dividend Ex-Date- Current Ratio1.25 EPS Y/Y TTM29.85% Oper. Margin0.00% RSI (14)55.00 Volatility11.91% 16.25%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price20.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-52.74% Payout- Rel Volume0.65 Prev Close3.77
Sales Surprise- EPS Surprise-29.00% Sales Q/Q- EarningsMar 26 BMO Avg Volume23.95K Price4.26
SMA206.79% SMA5018.61% SMA200-33.57% Trades Volume15,474 Change13.03%
Mar-26-24 07:30AM
Feb-27-24 07:31AM
07:30AM
Feb-07-24 07:30AM
Dec-29-23 07:30AM
07:10AM Loading…
Nov-17-23 07:10AM
07:00AM
Nov-15-23 04:15PM
Oct-31-23 08:58AM
Oct-12-23 08:02AM
Oct-02-23 08:58AM
Sep-27-23 08:58AM
Sep-26-23 08:58AM
Sep-22-23 11:27AM
Sep-21-23 10:00AM
07:58AM Loading…
Sep-18-23 07:58AM
Sep-05-23 09:00AM
Aug-28-23 08:58AM
Aug-14-23 09:00AM
Aug-10-23 08:58AM
Jul-24-23 07:00AM
Jul-13-23 08:58AM
Jun-21-23 08:00AM
Jun-20-23 04:10PM
Jun-13-23 08:58AM
May-12-23 04:08PM
May-10-23 07:15AM
May-09-23 07:15AM
May-04-23 08:58AM
May-02-23 03:30PM
08:58AM Loading…
Apr-27-23 08:58AM
Apr-05-23 08:58AM
Mar-28-23 08:58AM
Mar-22-23 08:58AM
Feb-13-23 08:58AM
Jan-31-23 08:58AM
Jan-18-23 09:00AM
Jan-10-23 09:00AM
Jan-04-23 09:00AM
Dec-14-22 09:00AM
Nov-09-22 09:00AM
Oct-13-22 06:29AM
Aug-24-22 09:00AM
Aug-15-22 09:00AM
Jul-22-22 11:32AM
Jul-05-22 09:00AM
Jul-01-22 04:04PM
06:33AM
Jun-30-22 06:44AM
04:00AM
Jun-29-22 04:06PM
11:30AM
09:32AM
Jun-28-22 07:08PM
05:01PM
04:37PM
11:14AM
Jun-27-22 12:13PM
09:00AM
Jun-24-22 12:25PM
Jun-23-22 04:34PM
04:00AM
May-19-22 09:00AM
May-16-22 09:00AM
May-06-22 06:12AM
May-05-22 09:00AM
Apr-26-22 09:00AM
Mar-31-22 09:00AM
Mar-22-22 09:00AM
04:00AM
Mar-15-22 01:45PM
10:06AM
09:00AM
Feb-15-22 09:00AM
Feb-10-22 09:00AM
Jan-21-22 11:00AM
Jan-18-22 09:00AM
Jan-04-22 09:20AM
Dec-28-21 08:00AM
Dec-20-21 08:00AM
Dec-08-21 08:00AM
Dec-01-21 07:16AM
Nov-27-21 08:04AM
Nov-15-21 08:00AM
Nov-10-21 08:00AM
Oct-20-21 07:00AM
Oct-06-21 09:00AM
Oct-01-21 08:00AM
Sep-20-21 09:00AM
Sep-16-21 01:00PM
Sep-14-21 02:49PM
12:27PM
10:11AM
09:05AM
Sep-13-21 07:07AM
Sep-02-21 09:00AM
Aug-26-21 02:51PM
09:00AM
Aug-19-21 07:07AM
05:11AM
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.